相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV
Engie Salama et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2021)
Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment
Dario Cattaneo et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Prostate cancer in sexual minorities and the influence of HIV status
Channa Amarasekera et al.
NATURE REVIEWS UROLOGY (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV
A. Borghetti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF
Dario Cattaneo et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2018)
Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer
Salin Nhean et al.
AIDS (2018)
Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters
Johanna Weiss et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2017)
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
Guillemette E. Benoist et al.
CLINICAL PHARMACOKINETICS (2016)
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
Sherene Min et al.
AIDS (2011)